Free Trial

Repligen (RGEN) Stock Price, News & Analysis

-0.62 (-0.39%)
(As of 05/24/2024 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
362,300 shs
Average Volume
523,088 shs
Market Capitalization
$8.84 billion
P/E Ratio
Dividend Yield
Price Target

Repligen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
25.0% Upside
$197.75 Price Target
Short Interest
8.51% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.71mentions of Repligen in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$7.55 M Sold Last Quarter
Proj. Earnings Growth
From $1.46 to $2.03 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.40 out of 5 stars

Medical Sector

111th out of 923 stocks

Biological Products, Except Diagnostic Industry

11th out of 152 stocks

RGEN stock logo

About Repligen Stock (NASDAQ:RGEN)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Stock Price History

RGEN Stock News Headlines

RGEN Quantitative Stock Analysis
Positive Report for Repligen (RGEN) from Craig-Hallum
Repligen Corporation Common Stock (RGEN)
RBC Capital Remains a Buy on Repligen (RGEN)
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
9 Analysts


Net Income
$41.58 million
Pretax Margin


Sales & Book Value

Annual Sales
$638.76 million
Cash Flow
$3.03 per share
Book Value
$35.31 per share


Free Float
Market Cap
$8.84 billion

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

RGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price target for 2024?

9 brokerages have issued 1 year price objectives for Repligen's stock. Their RGEN share price targets range from $170.00 to $220.00. On average, they predict the company's share price to reach $197.75 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2024?

Repligen's stock was trading at $179.80 at the start of the year. Since then, RGEN shares have decreased by 12.0% and is now trading at $158.16.
View the best growth stocks for 2024 here

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our RGEN earnings forecast

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) released its quarterly earnings results on Wednesday, May, 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by $0.01. The biotechnology company earned $151.31 million during the quarter, compared to the consensus estimate of $150.06 million. Repligen had a net margin of 2.44% and a trailing twelve-month return on equity of 3.95%. Repligen's revenue for the quarter was down 17.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.64 EPS.

What guidance has Repligen issued on next quarter's earnings?

Repligen updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of 1.420-1.490 for the period, compared to the consensus EPS estimate of 1.460. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $635.6 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Who are Repligen's major shareholders?

Repligen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.13%), Price T Rowe Associates Inc. MD (6.39%), Brown Capital Management LLC (2.07%), Bank of New York Mellon Corp (2.03%), Conestoga Capital Advisors LLC (1.34%) and William Blair Investment Management LLC (1.14%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
This page (NASDAQ:RGEN) was last updated on 5/27/2024 by Staff

From Our Partners